Patients with symptomatic in-stent restenosis (ISR) of the superficial femoral artery (SFA) or proximal popliteal artery have better primary patency at 1 year if they received a drug-coated balloon ...

Hollywood, FL—Angioplasty with a drug-coated balloon for the treatment of in-stent restenosis of the superficial femoral artery (SFA) achieves significantly better patency at 12 months compared with ...

Please provide your email address to receive an email when new articles are posted on . At 1 year, use of a paclitaxel-coated balloon in the femoropopliteal segment resulted in greater rates of ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. CHICAGO — Three-year data from the IN.PACT SFA trial ...

SAN FRANCISCO -- A drug-coated balloon showed durable benefit over standard angioplasty in symptomatic femoropopliteal peripheral artery disease (PAD) in 2-year results from the IN.PACT SFA trial. The ...

HOLLYWOOD, Florida – Five-year results of the IN.PACT trials in the U.S. and Europe show that drug-coated balloon angioplasty is superior to plain balloon angioplasty in treating patients with ...

WASHINGTON, DC — The Stellarex (Spectranetics) drug-coated balloon (DCB) achieved better angiographic and clinical outcomes than standard balloon angioplasty in a complex clinical trial population ...

SINGAPORE, Sept. 15, 2020 /PRNewswire/ -- Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the FUTURE SFA (Randomized ...

SAN FRANCISCO, CA — Superior femoropopliteal artery (SFA) patency seen at 1 year with a drug-coated balloon (DCB) held firm at the 2-year follow-up in a large international randomized trial that ...

Medtronic's new year has started on a positive note with its IN.PACT Admiral drug-coated balloon getting approved by the U.S. Food and Drug Administration Monday. The FDA approval follows positive ...

SAN FRANCISCO, CA – NOVEMBER 11, 2011 – A clinical trial of patients with diabetes has demonstrated that cryoplasty post-dilitation compared to conventional balloon angioplasty in the superficial ...

MINNEAPOLIS--(BUSINESS WIRE)-- Expanding its commitment to developing innovative treatments for cardiovascular disease and the evidence to support their adoption, Medtronic, Inc. (NYSE: MDT) announced ...